Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Thursday, July 11, 2013

Phase III Study (MM-020/IFM 07-01) of Oral REVLIMIDA (Lenalidomide)...

Phase III Study of Oral REVLIMID A in Newly-Diagnosed Multiple Myeloma Meets Primary Endpoint )--Celgene International SA rl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMIDA in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of ... (more)

http://eon.businesswire.com/news/eon/20130711005636/en/Phase-III-Study-MM-020IFM-07-01-Oral-REVLIMID%C2%AE

No comments:

Post a Comment

Popular Stem Cell Roundup Posts